Utility of voriconazole therapeutic drug monitoring: A meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 7, 2016, Pages 1786-1799

  Luong, Me Linh ^a   Al Dabbagh, Mona ^b,c   Groll, Andreas H ^d   Racil, Zdenek ^e   Nannya, Yasuhito ^f   Mitsani, Dimitra ^g   Husain, Shahid ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^f UNIVERSITY OF TOKYO   (Japan)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE; ANTIFUNGAL AGENT;

ARTICLE; BIBLIOGRAPHIC DATABASE; BRAIN DISEASE; CARDIOTOXICITY; CONCENTRATION LOSS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EMBASE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MEDLINE; METABOLIC DISORDER; NEUROTOXICITY; NIGHTMARE; OUTCOME ASSESSMENT; OVID DATABASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN MANIFESTATION; SURVIVAL RATE; SYSTEMATIC REVIEW; VISUAL DISORDER; BLOOD; INVASIVE FUNGAL INFECTIONS; META ANALYSIS; MYCOSES; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; DRUG MONITORING; HUMANS; INVASIVE FUNGAL INFECTIONS; MYCOSES; TREATMENT OUTCOME; VORICONAZOLE;

EID: 84979035694     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw099     Document Type: Article

References (36)

1. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Exp Review Anti-infective Ther 2004; 2: 485-97
2. Walsh TJ, Anaissie EJ, Denning DWet al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60
3. Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin 2013; 29 Suppl 4: 13-8
4. vanWanrooy MJ, Span LF, Rodgers MG et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother 2014; 58: 7098-101
5. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasivemycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11
6. Miyakis S, van Hal SJ, Ray J et al. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16: 927-33
7. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 55: 4782-8
8. Tan K, Brayshaw N, Tomaszewski K et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235-43
9. Miyakis S, van Hal SJ, Solvag CJ et al. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. Therapeutic Drug Mon 2010; 32: 661-4
10. Ashbee HR, Barnes RA, Johnson EM et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69: 1162-76
11. Laverdiere M, Bow EJ, Rotstein C et al. Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol 2014; 25: 327-43
12. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
13. Wells GA, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
14. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2
15. Trifilio S, Singhal S, Williams S et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40: 451-6
16. Gomez-Lopez A, Cendejas-Bueno E, Cuesta I et al. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. Med Mycol 2012; 50: 439-45
17. Choi SH, Lee SY, Hwang JY et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer 2013; 60: 82-7
18. Lee YJ, Lee SO, Choi SH et al. Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies. Med Mycol 2013; 51: 324-30
19. Neely M, Rushing T, Kovacs A et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50: 27-36
20. Imhof A, Schaer DJ, Schanz U et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Weekly 2006; 136: 739-42
21. Kim SH, Yim DS, Choi SM et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis 2011; 15: e753-8
22. Bruggemann RJ, van der Linden JW, Verweij PE et al. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J 2011; 30: 533-4
23. Matsumoto K, Ikawa K, Abematsu K et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009; 34: 91-4
24. Suzuki Y, Tokimatsu I, Sato Yet al. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clinica Chimica Acta 2013; 424: 119-22
25. Okuda T, Okuda A, Watanabe N et al. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection. Yakugaku Zasshi: J Pharmaceut Soc Japan 2008; 128: 1811-8
26. Ueda K, Nannya Y, Kumano K et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 89: 592-9
27. Dolton MJ, Ray JE, Chen SC et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56: 4793-9
28. Mitsani D, Nguyen MH, Shields RK et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012; 56: 2371-7
29. Racil Z, Winterova J, Kouba M et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses 2012; 55: 483-92
30. Pieper S, Kolve H, Gumbinger HG et al. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother 2012; 67: 2717-24
31. Park WB, Kim NH, Kim KH et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55: 1080-7
32. Soler-Palacin P, Frick MA, Martin-Nalda A et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother 2012; 67: 700-6
33. Chu HY, Jain R, Xie H et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis 2013; 13: 105
34. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83
35. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA et al. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 2006; 43: 1449-55
36. Hamada Y, Seto Y, Yago K et al. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical metaanalysis. J Infect Chemother 2012; 18: 501-7